Valeant Merger Talks With Actavis Said to Stall on Price

Valeant Pharmaceuticals International Inc.’s merger talks with Actavis Inc. have stalled because of a disagreement on price, according to people familiar with the matter.

The generic-drug makers had sought to announce a deal as soon as today before Actavis balked at the premium offered by Valeant, said one of the people, who asked not to be identified because the discussions aren’t public. While the talks have halted for now, they may become active again, another person said.